格利特-ADL测试的切断值用于区分心力衰竭患者的功能状态
Habibe Durdu1,2, Melih Zeren3, Ertan Aydin4
1Giresun University, Department of Therapy and Rehabilitation, Vocational School of Health Services, Giresun, Türkiye. habibe_durdu@hotmail.com.
Irish journal of medical science
|January 27, 2026
概括
日常生活中的Glittre活动 (TGlittre) 测试具有5.05分钟的截止时间,用于识别心力衰竭 (HF) 患者的功能障碍. 这个TGlittre值与6分钟步行测试 (6MWT) 相对应,有助于评估HF功能状态.
科学领域:
- 心脏病学 心脏病学
- 康复医学 康复医学 康复医学
- 临床评估 临床评估
背景情况:
- 日常生活中的Glittre活动 (TGlittre) 测试是一种功能评估工具,反映了日常任务,并被患者耐受好.
- 心力衰竭 (HF) 的管理需要准确的功能状态评估.
研究的目的:
- 为了确定TGlittre测试的截止值,相当于400米六分钟步行测试 (6MWT) 的值.
- 用TGlittre测试来识别心力衰竭患者的功能状况受损.
主要方法:
- 一项涉及78名心力衰竭患者的横截面研究.
- 患者按随机顺序执行了6MWT和TGlittre测试.
- 使用接收器操作特征 (ROC) 分析来确定TGlittre切线值.
主要成果:
- 5.05分钟的TGlittre切线与6MWT400米的值相对应 (AUC:0.92).
- 患有TGlittre时间≥5.05分钟的患者表现出较低的体力活动和较高的明尼苏达州心力衰竭问卷 (MLHF-Q) 得分.
- 此组还显示了NYHA FCIII的更高患病率和较低的平均左心室喷射率 (LVEF).
结论:
- 5.05分钟的TGlittre测试截止时间是心力衰竭中功能状况受损的敏感和特定指标.
- 这一TGlittre值与HF患者的临床特征较差有关.
- TGlittre测试是一种有价值的客观工具,用于评估心力衰竭患者的功能能力,包括老年人.
相关概念视频
01:17Pathophysiology of Heart Failure
3.4K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.4K
01:27Heart Failure I: Introduction
829
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
829
01:29Heart Failure II: Pathophysiology
855
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
855
01:22Heart Failure Drugs: Diuretics
935
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
935
01:30Heart Failure V: Medical Management
267
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
267
01:22Heart Failure VI: Adjunct Therapies
313
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
313